The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care
The division is expected to grow to over a 100-member strong team by 2022
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
It has planned an investment of over Rs 80 crore in the next five years
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
Subscribe To Our Newsletter & Stay Updated
